The consumer watchdog says drug company GlaxoSmithKline was ambiguous but not misleading when it blamed federal government policy for hiking the price of its Panadol Osteo painkillers.
"There can be a fine line between an ambiguous statement and a misleading one," Australian Competition and Consumer Commission chairman Rod Sims said on Monday, finding there wasn't enough evidence to show the company contravened consumer laws.
Health Minister Sussan Ley asked the ACCC to investigate when the company said it would hike prices of Panadol Osteo following the government's decision to remove it from the Pharmaceutical Benefits Scheme from January 1, 2016.
